ASCO
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
Dr Bishal Gyawali on curiosity, communication and global oncology: touchONCOLOGY Future Leaders 2026
In this Future Leaders interview, Dr Gyawali discusses how patient-centered care, evidence-based practice and mentorship have shaped his career, and why curiosity, resilience and purpose are essential for the next generation of oncologists.
In this Future Leaders interview, Dr Soniya Dulal discusses the global mentors who shaped her career, the importance of building sustainable oncology systems in Nepal and how precision medicine, palliative care and international collaboration can improve patient outcomes in resource-limited settings.
At EAU26, Dr Juan Gómez Rivas reflected on a period of rapid transformation in the field. Across mentorship, technology and precision medicine, Dr Gómez Rivas believes the field is entering a new era. For urologists, he says, the message is simple: embrace innovation, collaborate widely and keep patients at the centre of every advance.
Prof Bertrand Tombal reflected on how advances in imaging, evolving treatment strategies and persistent evidence gaps are reshaping the management of oligometastatic prostate cancer. In the conversation below, he discusses why the concept remains controversial, the promise and limitations of metastasis-directed therapy and how clinicians should navigate an increasingly complex treatment landscape.
At EAU26, Dr Karen Buch-Olsen and Professor Mads Hvid Aaberg Poulsen shared early insights from the PRISMA PET trial, a randomized study comparing conventional sodium fluoride PET CT with PSMA PET CT in newly diagnosed, high-risk prostate cancer patients.
At EAU26, Dr Kevin Keane presented early results from the G-DISCO trial, the first-in-human study exploring a streamlined intravesical approach for patients with BCG-unresponsive non–muscle-invasive bladder cancer.
At #EAU26, Professor Dickon Hayne presented early findings from the ZiPUP study. This is a phase I trial exploring a novel PET imaging approach in urothelial cancer. In this interview, he discusses the unmet need in staging, the study’s design and what the preliminary data might mean for clinical practice.
At EAU26, Prof Dickon Hayne presented findings from the ANZUP 1301 (BCG+MM) trial. With global BCG shortages and ongoing challenges around tolerability, the study offers timely insights into how combination intravesical strategies may deliver comparable efficacy while improving patient experience and resource utilisation.
Microplastics have been detected across the human body – but what they mean for cancer risk remains unclear. At the recent ASCO GU26, presented early data suggesting these particles are not only present in the prostate, but may be more concentrated in tumour tissue. The findings raise provocative questions about environmental exposures and carcinogenesis, while underscoring just how much remains unknown.
At the recent 2026 ASCO Genitourinary Cancers Symposium (ASCO GU26), Dr Jeannie Hoffman-Censits (The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Center, Baltimore, MD, USA) presented data from ECOG-ACRIN EA8192 cohort C, exploring a new approach for patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) who are ineligible for cisplatin. With neoadjuvant options limited in this population, the trial assessed whether combining chemotherapy with immunotherapy could improve outcomes.
The 2026 ASCO Genitourinary Cancers Symposium showcased pivotal advances across renal, prostate and bladder cancers. Key late-breaking trials across kidney, prostate and bladder cancer highlighted promising combinations, novel targeted therapies and innovative radioligand approaches, demonstrating improved disease control, progression-free survival and ...
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
As we begin 2026, Dr Ana Tecic Vuger (University Hospital for Tumors, Zagreb, Croatia) reflects on the major breakthroughs throughout 2025. The breast cancer community has witnessed transformative progress across the continuum of research and clinical care, from more precise targeted therapies and novel endocrine strategies to advances in biomarker-driven treatment sequencing and survivorship. The major oncology meetings – ASCO 2025, ESMO/ESMO Breast 2025, and the San Antonio Breast Cancer Symposium (SABCS) 2025 – offered a rich tapestry of data that helps shape practice and sharpen research priorities.
The treatment paradigm for HER2-positive advanced gastric and GEJ adenocarcinoma has been reshaped by the integration of immune checkpoint inhibitors into trastuzumab-based chemotherapy. The phase III KEYNOTE-811 trial established the benefit of adding pembrolizumab to trastuzumab and chemotherapy, whereas the HERIZON-GEA-01 trial, presented at 2026 ASCO GI Cancers Symposium, explored a distinct strategy – enhancing HER2 blockade itself through substitution with the bispecific antibody zanidatamab, with or without PD-1 inhibition.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1)Â and cytotoxic T lymphocyte-associated antigen 4Â (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2Â The ability of tumours ...
touchONCOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
